An observational study in Parkinson Disease, sponsored by Acibadem University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Acibadem University · Observational
This study aims to evaluate the validity and reliability of the Turkish version of the Cognitive Self-Efficacy Questionnaire in individuals with Parkinson's disease.
4,484 studies on the registry are indexed under Parkinson Disease; 1,081 are open to participants now.
This study's planned enrollment of 100 is close to the median of 96 across 1,056 observational studies indexed under Parkinson Disease.
Browse Parkinson Disease studies →Acibadem University is the lead sponsor of 210 studies on the registry; 50 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of individuals diagnosed with Parkinson's disease who are attending the Movement Disorders Outpatient Clinic at the Department of Neurology, Istanbul Cerrahpaşa Faculty of Medicine Hospital. Eligible participants will be between 40 and 85 years of age, have sufficient cognitive function to communicate (MMSE ≥ 24), and provide informed consent. A total of 100 patients will be recruited for the study.
Exclusion Criteria:
Participants will complete the Turkish version of the Cognitive Self-Efficacy Questionnaire to assess cognitive self-efficacy. The questionnaire will be administered for the evaluation of its validity and reliability in individuals with Parkinson's disease.
Validity and Reliability of the Turkish Version of the Cognitive Self-Efficacy Questionnaire (CSEQ)
Assessment of the psychometric properties of the Turkish version of the CSEQ in individuals with Parkinson's disease, including internal consistency (Cronbach's alpha), test-retest reliability (intraclass correlation coefficient), and construct validity through factor and correlation analyses.
Time frame: Baseline and 14-21 days for test-retest assessment
Self-Efficacy for Managing Chronic Disease (6-Item Scale)
Assessment of perceived self-efficacy in managing chronic disease using the 6-Item Self-Efficacy for Managing Chronic Disease Scale. The scale evaluates individuals' confidence in managing symptoms such as pain, fatigue, emotional distress, and disease-related problems. It consists of 6 items scored on a 10-point Likert scale (1 = not at all confident, 10 = totally confident), with the total score calculated as the mean of all items. Higher scores indicate greater self-efficacy in disease management. The validated Turkish version will be used.
Time frame: Baseline
Montreal Cognitive Assessment (MoCA-TR)
Cognitive function will be assessed using the Turkish version of the Montreal Cognitive Assessment (MoCA-TR). This screening tool evaluates multiple cognitive domains including visuospatial/executive functions, naming, attention, language, abstraction, delayed recall, and orientation. The total score ranges from 0 to 30, with higher scores indicating better cognitive function. The validated Turkish version for Parkinson's disease will be used.
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acibadem University